Story Stock – 10/02/2001
15:33 ET ****** Fed Myths : The silliness that always accompanies Fed meeting never ceases to amaze, so let’s get right to the task of dispelling the myths. Myth 1: The Fed is running out of ammunition. This myth is propagated by pessimists who want you to believe that the Fed can’t do much more for the economy now that the funds rate is down to 2.50%. But by our tally, that leaves 250 bp more of rate cuts in the arsenal, which can make a significant difference to business borrowers and households with mortgages. Beyond that, the Fed can just pump reserves into the system even with rates at zero (the Bank of Japan is doing that now). We probably won’t get to that point, but it’s important to understand that the Fed still has plenty of ammunition. Myth 2: the Fed needs to stop cutting rates because it risks undermining confidence and hurts those who depend on deposit rates. This is probably the silliest of the myths. There are still those who believe that the Fed can make everything better by pretending everything is better. Psychology has a role in any economy, but the idea that the economy is nothing but a con game is false. If the economy is hurting, the Fed does not help matters by leaving rates high and telling us that everything is rosy (they kept rates high in the early 1930s, and that didn’t work so well). Also, though depositors can be hurt by lower rates, we know for a fact that lower rates, on the whole, stimulate growth. Myth 3: The 50 bp rate cut must mean that the economy is worse than we feared. OK, maybe this is the silliest of the bunch. Let’s make one point clear: the Fed knows just as much about the economy right now as the rest of us, which is not much. After the Sep 11 attacks, the economic outlook is more clouded than ever and only the passage of time will clarify the outlook. The idea that the Fed has more information that confirms a bleaker outlook presumes that such information exists. Even if the Fed already knew Friday’s employment report (which it doesn’t), that would hardly matter. Who really believes that a report detailing the economy in the week of Sep 14 tells us anything about the future? The Fed cut rates aggressively today because the country just suffered an unprecedented attack at a time of economic vulnerability – to quibble about 25 bp in this environment would have been irresponsible. So here are the real takeaways today: 1) the Fed cut 50 bp because it was the right thing to do, 2) the Fed, like the rest of us, doesn’t know what is coming next, 3) Fed rate cuts are most definitely good for the economy, and 4) the Fed has plenty of ammunition left to lift the economy should it become necessary. – Greg Jones, Briefing.com |
08:52 ET ****** Stocks to Watch : The truth of the matter is that there is a “market to watch” as all stocks will be in play to a certain extent given that there is an FOMC meeting today. The Fed’s policy decision is due around 14:15 ET, and it is Briefing.com’s expectation– and the consensus expectation– that the Fed will cut rates by an additional 50bp bringing the fed funds rate to 2.50%. That understanding hasn’t done much to bolster the market, though, as current indications suggest the cash market will start the day on a modestly lower note. Presently, the S&P futures are trading approximately 2 points below fair value while the Nasdaq 100 futures are 8 points below fair value. The lackluster tone has been driven by weakness in European bourses and some disheartening earnings warnings after the close yesterday from a host of companies, including Compaq (CPQ 7.85 -0.48), McGraw-Hill (MHP 56.90), and Abercrombie & Fitch (ANF 15.75 -0.85). Those stocks will be standouts in their respective sectors (i.e. computer, publishing, and retail), but, of course, they won’t be the only stocks worth watching. Bullish investors will want to keep their eye on the airlines as they are getting a vote of confidence from Merrill Lynch, which upgraded DAL, ALK, and ACAI to NT ACCUMULATE from Neutral. Separately, Goldman Sachs upgraded SkyWest (SKYW 17.17) to REC. LIST from Mkt Outperform… Biotech stocks should attract some added interest as Andrx (ADRX 70.90 +1.90) was tapped to replace ATHM (now ATHMQ) in the Nasdaq 100 index after the latter company filed for bankruptcy. The inclusion of ADRX will take place before the open on Oct. 4; meanwhile, the replacement of EXDS in the Nasdaq 100 by Gilead Sciences (GILD 56.62) has been moved up from Oct. 5 and will take place Oct. 4 as well… A few pharmaceutical companies making the news this morning… In particular, Johnson & Johnson (JNJ 55.42) and Baxter (BAX 55.50)— both of which were downgraded by UBS Warburg to HOLD from Strong Buy due to valuation… For more detail on these, and other developments, be sure to visit Briefing.com’s In Play page.– Patrick J. O’Hare, Briefing.com |